Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$820M |
| 2 |
Palo Alto Networks
PANW
|
+$358M |
| 3 |
Visa
V
|
+$355M |
| 4 |
CELG
Celgene Corp
CELG
|
+$339M |
| 5 |
Citigroup
C
|
+$325M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$722M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$356M |
| 3 |
Alibaba
BABA
|
+$345M |
| 4 |
EOG Resources
EOG
|
+$344M |
| 5 |
Canadian Pacific Kansas City
CP
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.08% |
| 2 | Consumer Discretionary | 17.25% |
| 3 | Communication Services | 14.3% |
| 4 | Technology | 13.13% |
| 5 | Financials | 9.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GWPH
451
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $17.6M | 0.02% |
192,343
-31,462
| -14% | -$3.5M |
|
452
Freeport-McMoran
FCX
$91.2B
| $17.6M | 0.02% |
1,812,626
-104,924
| -5% | -$1.26M |
|
453
CALL
Cigna
CI
$76.1B
| $17.6M | 0.02% |
130,000
| – | – |
|
454
Mercado Libre
MELI
$95.6B
| $17.5M | 0.02% |
192,186
-155,326
| -45% | -$18.3M |
|
|
CPPL
455
DELISTED
Columbia Pipeline Partners LP
CPPL
| $17.5M | 0.02% |
1,380,367
-1,692,526
| -55% | -$34.4M |
|
|
VISN
456
Vistance Networks Inc
VISN
$2.64B
| $17.4M | 0.02% |
+580,266
| New | +$18M |
|
457
Marcus & Millichap
MMI
$1.18B
| $17.3M | 0.02% |
376,084
-121,572
| -24% | -$5.7M |
|
|
CIM
458
Chimera Investment
CIM
$1.06B
| $16.8M | 0.02% |
418,539
+13,928
| +3% | +$587K |
|
|
ROIC
459
DELISTED
Retail Opportunity Investments Corp.
ROIC
| $16.6M | 0.02% |
1,001,474
+290,972
| +41% | +$4.81M |
|
|
NXTM
460
DELISTED
NxStage Medical Inc.
NXTM
| $16.6M | 0.02% |
1,049,780
+112,792
| +12% | +$1.81M |
|
|
ITCI
461
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $16.1M | 0.02% |
+402,000
| New | +$13.1M |
|
462
Dorman Products
DORM
$3.98B
| $15.9M | 0.02% |
312,008
+297,770
| +2,091% | +$14.9M |
|
|
DWRE
463
DELISTED
DEMANDWARE INC COM STK (DE)
DWRE
| $15.8M | 0.02% |
+305,900
| New | +$18.9M |
|
464
PUT
BioMarin Pharmaceuticals
BMRN
$11.7B
| $15.8M | 0.02% |
150,000
+30,000
| +25% | +$4.01M |
|
465
IMAX
IMAX
$2.61B
| $15.8M | 0.02% |
467,414
+52,200
| +13% | +$1.81M |
|
|
GBT
466
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15.6M | 0.02% |
+369,531
| New | +$17.4M |
|
|
NVRO
467
DELISTED
NEVRO CORP.
NVRO
| $15.1M | 0.02% |
326,410
+189,650
| +139% | +$9.19M |
|
468
BioCryst Pharmaceuticals
BCRX
$2.35B
| $15.1M | 0.02% |
1,324,549
+6,832
| +0.5% | +$91.2K |
|
|
KDNY
469
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $15.1M | 0.02% |
156,253
+6,273
| +4% | +$747K |
|
470
RPC Inc
RES
$1.2B
| $15.1M | 0.02% |
+1,703,339
| New | +$19.4M |
|
|
DVAX
471
DELISTED
Dynavax Technologies
DVAX
| $15M | 0.02% |
+611,938
| New | +$17.3M |
|
472
United Natural Foods
UNFI
$3.01B
| $14.9M | 0.02% |
306,512
-10,364
| -3% | -$532K |
|
|
ZOES
473
DELISTED
Zoe's Kitchen, Inc.
ZOES
| $14.8M | 0.02% |
375,347
-32,608
| -8% | -$1.27M |
|
474
Varonis Systems
VRNS
$4.59B
| $14.7M | 0.02% |
2,828,904
+696,252
| +33% | +$4.85M |
|
|
TSRO
475
DELISTED
TESARO, Inc.
TSRO
| $14.6M | 0.02% |
364,420
+111,746
| +44% | +$6.11M |
|
Similar funds
Jennison Associates's Q3 2015 Portfolio in Review
As of Q3 2015, Jennison Associates held 813 positions worth $97.6B, down 11% from $109B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jennison Associates's Q3 2015 filing shows 84 new, 272 increased, 353 reduced and 92 closed positions. Its largest new stake was Palo Alto Networks: 12,124,434 shares worth $348M. The largest sale was Gilead Sciences, an estimated $722M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q3 2015 buy was Palo Alto Networks: 12,124,434 shares worth $348M.
- Jennison Associates added most to Alphabet (Google) Class C in Q3 2015, an estimated $820M increase.
- Jennison Associates's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $722M.
- Jennison Associates fully exited KRAFT FOODS GROUP INC COM STK (VA) in Q3 2015, selling an estimated $144M.
- Jennison Associates's ten largest holdings make up 24% of its $97.6B portfolio in Q3 2015.
- Jennison Associates opened 84 new positions and closed 92 in Q3 2015.
- Jennison Associates's portfolio value fell 11% quarter-over-quarter to $97.6B.
Based on Jennison Associates's 13F filing for Q3 2015, filed 6 Nov 2015.